Literature DB >> 28218755

Changes in the incidence, patterns and outcomes of graft failure following hematopoietic stem cell transplantation for Hurler syndrome.

S H Lum1, W P Miller2, S Jones3, K Poulton4, W Ogden5, H Lee4, A Logan4, D Bonney1, T C Lund2, P J Orchard2, R F Wynn1.   

Abstract

Hematopoietic stem cell transplantation (HSCT) is the standard of care in children with Hurler syndrome (HS) as it is the only therapy that can arrest disease progression. We examined the incidence, patterns and outcomes of graft failure in all HS children undergoing first HSCT at the Royal Manchester Children's Hospital or the University of Minnesota Children's Hospital from 1983 to 2016. Implementation of busulfan pharmacokinetic monitoring started in 2004 in both institutions. Two hundred and forty HS children were included in this analysis (historical era (pre-2004), n=131; current era (post 2004), n=109). The proportion of patients with graft failure was significantly lower in the current era compared with the historical era (37.2% vs 10.1%, respectively). Of 49 patients with graft failure in the historical era, 1 had aplasia and 48 had autologous reconstitution. All the 11 graft failures of the current era occurred in recipients of cord blood transplants (7 aplasia and 4 autologous reconstitution). The outcomes of second transplant in these patients has improved, with 89% of such patients alive and engrafted in the current era compared with 58% in the historical era. The pattern of graft failure has changed from autologous reconstitution, likely secondary to inadequate myelosuppression in the historical era, to aplasia in the current era, likely due to imperfect immunosuppression.

Entities:  

Mesh:

Year:  2017        PMID: 28218755     DOI: 10.1038/bmt.2017.5

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  21 in total

1.  Umbilical cord blood transplantation for children with thalassemia and sickle cell disease.

Authors:  Annalisa Ruggeri; Mary Eapen; Andromachi Scaravadou; Mitchell S Cairo; Monica Bhatia; Joanne Kurtzberg; John R Wingard; Anders Fasth; Luca Lo Nigro; Mouhab Ayas; Duncan Purtill; Karim Boudjedir; Wagnara Chaves; Mark C Walters; John Wagner; Eliane Gluckman; Vanderson Rocha
Journal:  Biol Blood Marrow Transplant       Date:  2011-01-28       Impact factor: 5.742

2.  Outcomes after related and unrelated umbilical cord blood transplantation for hereditary bone marrow failure syndromes other than Fanconi anemia.

Authors:  Renata Bizzetto; Carmen Bonfim; Vanderson Rocha; Gérard Socié; Franco Locatelli; Kawah Chan; Oscar Ramirez; Joel Stein; Samir Nabhan; Eliana Miranda; Jakob Passweg; Carmino Antonio de Souza; Eliane Gluckman
Journal:  Haematologica       Date:  2010-11-11       Impact factor: 9.941

3.  Unrelated cord blood transplantation for newly diagnosed patients with severe acquired aplastic anemia using a reduced-intensity conditioning: high graft rejection, but good survival.

Authors:  H-L Liu; Z-M Sun; L-Q Geng; X-B Wang; K-Y Ding; B-I Tang; J Tong; Z-Y Wang
Journal:  Bone Marrow Transplant       Date:  2012-01-16       Impact factor: 5.483

4.  Management of mucopolysaccharidosis type IH (Hurler's syndrome) presenting in infancy with severe dilated cardiomyopathy: a single institution's experience.

Authors:  Daniel H Wiseman; Jean Mercer; Karen Tylee; Nilima Malaiya; Denise K Bonney; Simon A Jones; J Edmond Wraith; Robert F Wynn
Journal:  J Inherit Metab Dis       Date:  2012-06-21       Impact factor: 4.982

5.  Long-term outcome of Hurler syndrome following bone marrow transplantation.

Authors:  C B Whitley; K G Belani; P N Chang; C G Summers; B R Blazar; M Y Tsai; R E Latchaw; N K Ramsay; J H Kersey
Journal:  Am J Med Genet       Date:  1993-04-15

Review 6.  Cellular engineering and therapy in combination with cord blood allografting in pediatric recipients.

Authors:  M S Cairo; N Tarek; D A Lee; C Delaney
Journal:  Bone Marrow Transplant       Date:  2015-09-14       Impact factor: 5.483

Review 7.  Busulfan fludarabine vs busulfan cyclophosphamide as a preparative regimen before allogeneic hematopoietic cell transplantation: systematic review and meta-analysis.

Authors:  S Ben-Barouch; O Cohen; L Vidal; I Avivi; R Ram
Journal:  Bone Marrow Transplant       Date:  2015-10-12       Impact factor: 5.483

8.  Outcome of 27 patients with Hurler's syndrome transplanted from either related or unrelated haematopoietic stem cell sources.

Authors:  G Souillet; N Guffon; I Maire; M Pujol; P Taylor; F Sevin; N Bleyzac; C Mulier; A Durin; K Kebaili; C Galambrun; Y Bertrand; R Froissart; C Dorche; L Gebuhrer; C Garin; J Berard; P Guibaud
Journal:  Bone Marrow Transplant       Date:  2003-06       Impact factor: 5.483

9.  Prevalence of lysosomal storage disorders.

Authors:  P J Meikle; J J Hopwood; A E Clague; W F Carey
Journal:  JAMA       Date:  1999-01-20       Impact factor: 56.272

10.  Outcomes of hematopoietic stem cell transplantation for Hurler's syndrome in Europe: a risk factor analysis for graft failure.

Authors:  J J Boelens; R F Wynn; A O'Meara; P Veys; Y Bertrand; G Souillet; J E Wraith; A Fischer; M Cavazzana-Calvo; K W Sykora; P Sedlacek; A Rovelli; C S P M Uiterwaal; N Wulffraat
Journal:  Bone Marrow Transplant       Date:  2007-05-28       Impact factor: 5.483

View more
  15 in total

1.  Genetic testing of Mucopolysaccharidoses disease using multiplex PCR- based panels of STR markers: in silico analysis of novel mutations.

Authors:  Mehdi Shafaat; Mehrdad Hashemi; Ahmad Majd; Maryam Abiri; Sirous Zeinali
Journal:  Metab Brain Dis       Date:  2019-06-24       Impact factor: 3.584

Review 2.  Hematopoietic Stem Cell Transplantation for Mucopolysaccharidoses: Past, Present, and Future.

Authors:  Madeleine Taylor; Shaukat Khan; Molly Stapleton; Jianmin Wang; Jing Chen; Robert Wynn; Hiromasa Yabe; Yasutsugu Chinen; Jaap Jan Boelens; Robert W Mason; Francyne Kubaski; Dafne D G Horovitz; Anneliese L Barth; Marta Serafini; Maria Ester Bernardo; Hironori Kobayashi; Kenji E Orii; Yasuyuki Suzuki; Tadao Orii; Shunji Tomatsu
Journal:  Biol Blood Marrow Transplant       Date:  2019-02-14       Impact factor: 5.742

3.  The Outcome of Allogeneic Hematopoietic Stem Cell Transplantation From Different Donors in Recipients With Mucopolysaccharidosis.

Authors:  Yuhua Qu; Hao Liu; Likun Wei; Shushan Nie; Wenjiao Ding; Sha Liu; Haiyan Liu; Hua Jiang
Journal:  Front Pediatr       Date:  2022-06-30       Impact factor: 3.569

Review 4.  Current and Future Treatment of Mucopolysaccharidosis (MPS) Type II: Is Brain-Targeted Stem Cell Gene Therapy the Solution for This Devastating Disorder?

Authors:  Claire Horgan; Simon A Jones; Brian W Bigger; Robert Wynn
Journal:  Int J Mol Sci       Date:  2022-04-27       Impact factor: 6.208

5.  Hematopoietic stem cell transplantation in children with Griscelli syndrome type 2: a single-center report on 35 patients.

Authors:  M Al-Mofareh; M Ayas; A Al-Seraihy; K Siddiqui; A Al-Jefri; I Ghemlas; H Alsaedi; H El-Solh; S Al-Sweedan; B Al-Saud; H Al-Mousa; H Al-Dhekri; R Arnaout; R Mohammed; S Al-Muhsen; A Al-Ahmari
Journal:  Bone Marrow Transplant       Date:  2020-04-14       Impact factor: 5.483

6.  Early and late outcomes after cord blood transplantation for pediatric patients with inherited leukodystrophies.

Authors:  Brigitte T A van den Broek; Kristin Page; Annalisa Paviglianiti; Janna Hol; Heather Allewelt; Fernanda Volt; Gerard Michel; Miguel Angel Diaz; Victoria Bordon; Tracey O'Brien; Peter J Shaw; Chantal Kenzey; Amal Al-Seraihy; Peter M van Hasselt; Andrew R Gennery; Eliane Gluckman; Vanderson Rocha; Annalisa Ruggeri; Joanne Kurtzberg; Jaap Jan Boelens
Journal:  Blood Adv       Date:  2018-01-04

7.  Reduced-intensity single-unit unrelated cord blood transplant with optional immune boost for nonmalignant disorders.

Authors:  Mark T Vander Lugt; Xiaohua Chen; Maria L Escolar; Beth A Carella; Jessie L Barnum; Randy M Windreich; Memphis J Hill; Michelle Poe; Rebecca A Marsh; Heather Stanczak; Elizabeth O Stenger; Paul Szabolcs
Journal:  Blood Adv       Date:  2020-07-14

8.  Enzyme replacement therapy and hematopoietic stem cell transplant: a new paradigm of treatment in Wolman disease.

Authors:  Jane E Potter; Gemma Petts; Arunabha Ghosh; Fiona J White; Jane L Kinsella; Stephen Hughes; Jane Roberts; Adam Hodgkinson; Kathryn Brammeier; Heather Church; Christine Merrigan; Joanne Hughes; Pamela Evans; Helen Campbell; Denise Bonney; William G Newman; Brian W Bigger; Alexander Broomfield; Simon A Jones; Robert F Wynn
Journal:  Orphanet J Rare Dis       Date:  2021-05-21       Impact factor: 4.123

Review 9.  Therapeutic Options for Mucopolysaccharidoses: Current and Emerging Treatments.

Authors:  Kazuki Sawamoto; Molly Stapleton; Carlos J Alméciga-Díaz; Angela J Espejo-Mojica; Juan Camilo Losada; Diego A Suarez; Shunji Tomatsu
Journal:  Drugs       Date:  2019-07       Impact factor: 11.431

10.  Lower Exposure to Busulfan Allows for Stable Engraftment of Donor Hematopoietic Stem Cells in Children with Mucopolysaccharidosis Type I: A Case Report of Four Patients.

Authors:  Praveen Shukla; Christopher C Dvorak; Janel Long-Boyle; Sandhya Kharbanda
Journal:  Int J Mol Sci       Date:  2020-08-06       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.